Anti‐<scp>JC</scp> virus (<scp>JCV</scp>) antibody prevalence in the <scp>JCV</scp> Epidemiology in <scp>MS</scp> (<scp>JEMS</scp>) trial

Abstract

Overall seroprevalence of anti-JCV antibodies in MS patients from Europe, Canada and Australia was consistent with previous studies using the STRATIFY JCV assay. Anti-JCV prevalence differed significantly by age, gender and country, but no geographical pattern was evident. Disease and treatment type were not associated with differences in anti-JCV antibody status.